Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Guido Eibl

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3497-4527; OpenAlex author ID A5019257615; NIH RePORTER profile ID 7919731. Sources: OpenAlex.

Their work

Papers
59 (first author 7, last author 18)
Trials
0
Grants
5
Labs led
1
Collaborators
106
Papers, trials and grants by year

2011: 6 papers, 1 grant · 2012: 6 papers · 2013: 7 papers · 2014: 2 papers · 2015: 1 paper · 2016: 4 papers, 1 grant · 2017: 4 papers · 2018: 7 papers · 2019: 7 papers · 2020: 3 papers · 2021: 4 papers · 2022: 2 papers · 2023: 1 paper, 1 grant · 2024: 1 paper, 1 grant · 2025: 2 papers, 1 grant · 2026: 2 papers

Papers 50 of 59

  1. Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies. First author DOI 10.1038/s41392-025-02499-y↗
  2. Prevention Before Therapy in Pancreatic Ductal Adenocarcinoma: The Clinical, Economic, and Human Case for Weighting Resources Upstream. Co-author DOI 10.1158/1940-6207.capr-26-0197↗
  3. Self-amplifying NRF2-EZH2 epigenetic loop converts KRAS-initiated progenitors to invasive pancreatic cancer. Co-author DOI 10.1038/s43018-025-01003-3↗
  4. Stress and Obesity Signaling Converge on CREB Phosphorylation to Promote Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-24-0785↗
  5. Upregulated Matrisomal Proteins and Extracellular Matrix Mechanosignaling Underlie Obesity-Associated Promotion of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16081593↗
  6. Low dosage combination treatment with metformin and simvastatin inhibits obesity-promoted pancreatic cancer development in male KrasG12D mice. Last author DOI 10.1038/s41598-023-43498-9↗
  7. Body Mass Index Trajectories Across the Adult Life Course and Pancreatic Cancer Risk. Co-author DOI 10.1093/jncics/pkac066↗
  8. Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells: Implications for Targeted Therapy. Co-author DOI 10.1158/1535-7163.mct-21-0964↗
  9. Metformin: review of epidemiology and mechanisms of action in pancreatic cancer. Co-author DOI 10.1007/s10555-021-09977-z↗
  10. Direct Effects of Lipopolysaccharide on Human Pancreatic Cancer Cells. Last author DOI 10.1097/mpa.0000000000001790↗
  11. Obesity and Pancreatic Cancer: Insight into Mechanisms. Co-author DOI 10.3390/cancers13205067↗
  12. Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance. First author DOI 10.3390/cancers13205126↗
  13. Endocrine-exocrine signals in obesity-associated pancreatic cancer. Co-author DOI 10.1038/s41575-020-0324-6↗
  14. The Diverse Involvement of Cigarette Smoking in Pancreatic Cancer Development and Prognosis. Co-author DOI 10.1097/mpa.0000000000001550↗
  15. Pancreatic Macrophages: Critical Players in Obesity-Promoted Pancreatic Cancer. First author DOI 10.3390/cancers12071946↗
  16. KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops. Co-author DOI 10.1016/j.semcancer.2017.10.007↗
  17. Emerging Evidence for the Clinical Relevance of Pancreatic Cancer Exosomes. Co-author DOI 10.1097/mpa.0000000000001203↗
  18. Animal Models: Challenges and Opportunities to Determine Optimal Experimental Models of Pancreatitis and Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001335↗
  19. Metformin alters the duodenal microbiome and decreases the incidence of pancreatic ductal adenocarcinoma promoted by diet-induced obesity. Last author DOI 10.1152/ajpgi.00170.2019↗
  20. Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pa… Co-author DOI 10.1371/journal.pone.0216603↗
  21. Obesity-Induced Adipose Tissue Inflammation as a Strong Promotional Factor for Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/cells8070673↗
  22. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development. First author DOI 10.3748/wjg.v25.i15.1797↗
  23. Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer. Co-author DOI 10.1016/j.jand.2017.07.005↗
  24. Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survival. Last author DOI 10.1038/s41392-017-0005-2↗
  25. Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model. Co-author DOI 10.1038/s41598-018-24337-8↗
  26. Obesity and Pancreatic Cancer: Overview of Epidemiology and Potential Prevention by Weight Loss. Co-author DOI 10.1097/mpa.0000000000000974↗
  27. The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and D… Co-author DOI 10.1097/mpa.0000000000001037↗
  28. Deficiency in hormone-sensitive lipase accelerates the development of pancreatic cancer in conditional KrasG12D mice. Last author DOI 10.1186/s12885-018-4713-y↗
  29. Deficiencies in Natural Killer Cell Numbers, Expansion, and Function at the Pre-Neoplastic Stage of Pancreatic Cancer by KRAS Mutation in the Pancreas of Obese… Co-author DOI 10.3389/fimmu.2018.01229↗
  30. Direct growth-inhibitory effects of prostaglandin E2 in pancreatic cancer cells in vitro through an EP4/PKA-mediated mechanism. Last author DOI 10.1016/j.surg.2016.12.037↗
  31. Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice. Last author DOI 10.1371/journal.pone.0184455↗
  32. Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. Co-author DOI 10.2337/db16-1477↗
  33. Suppression of Gingival NK Cells in Precancerous and Cancerous Stages of Pancreatic Cancer in KC and BLT-Humanized Mice. Co-author DOI 10.3389/fimmu.2017.01606↗
  34. Long-term survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2015.12.024↗
  35. Robust Early Inflammation of the Peripancreatic Visceral Adipose Tissue During Diet-Induced Obesity in the KrasG12D Model of Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000000497↗
  36. Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000531↗
  37. Transcriptomic and CRISPR/Cas9 technologies reveal FOXA2 as a tumor suppressor gene in pancreatic cancer. Co-author DOI 10.1152/ajpgi.00035.2016↗
  38. E-cadherin expression in obesity-associated, Kras-initiated pancreatic ductal adenocarcinoma in mice. Last author DOI 10.1016/j.surg.2015.07.023↗
  39. Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Ca… Co-author DOI 10.1371/journal.pone.0114573↗
  40. Risk factors for pancreatic cancer: underlying mechanisms and potential targets. First author DOI 10.3389/fphys.2014.00490↗
  41. Evaluating dietary compounds in pancreatic cancer modeling systems. First author DOI 10.1007/978-1-62703-287-2_12↗
  42. Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells. Last author DOI 10.1016/j.bbamcr.2013.08.006↗
  43. miR-143 decreases COX-2 mRNA stability and expression in pancreatic cancer cells. Last author DOI 10.1016/j.bbrc.2013.08.042↗
  44. Role of pancreatic cancer-derived exosomes in salivary biomarker development. Co-author DOI 10.1074/jbc.m113.452458↗
  45. Ellagic acid and embelin affect key cellular components of pancreatic adenocarcinoma, cancer, and stellate cells. Co-author DOI 10.1080/01635581.2013.832779↗
  46. The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo. Co-author DOI 10.1097/mpa.0b013e318264ccae↗
  47. Metformin inhibits the growth of human pancreatic cancer xenografts. Co-author DOI 10.1097/mpa.0b013e31827aec40↗
  48. Evidence for activation of mutated p53 by apigenin in human pancreatic cancer. Co-author DOI 10.1016/j.bbamcr.2011.12.008↗
  49. The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. Co-author DOI 10.1053/j.gastro.2011.10.026↗
  50. Apigenin inhibits NNK-induced focal adhesion kinase activation in pancreatic cancer cells. Last author DOI 10.1097/mpa.0b013e31824d64d9↗

Grants 5

  1. Impact of dietary lipids on pancreas cancer initiation and progression UH2CA286583↗
  2. Core 1: Animal and Cell Model Core P01CA236585↗
  3. Interaction between Chronic Stress and Obesity in Pancreatic Cancer Progression R21CA258125↗
  4. Animal Core P01CA163200↗
  5. The role of n-3 polyunsaturated fatty acids in pancreatic cancer R01CA122042↗

Closest collaborators

The 25 strongest of 106 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Enrique Rozengurt · 20 shared papers, 2013–2026 · strength 3.92
  2. Oscar Joe Hines · 25 shared papers, 2011–2026 · strength 2.16
  3. Stephen Jacob Pandol · 11 shared papers, 2 shared grants, 2012–2024 · strength 1.75
  4. Juan Enrique Rozengurt · 3 shared grants, 2016–2024 · strength 1.55
  5. James W. Sinnett‐Smith · 11 shared papers, 2013–2025 · strength 1.24
  6. Hui-Hua Chang · 13 shared papers, 2013–2024 · strength 1.21
  7. Vay Liang W. Go · 7 shared papers, 2 shared grants, 2011–2024 · strength 1.05
  8. Yaroslav Teper · 5 shared papers, 2020–2025 · strength 1.02
  9. Heather R. Christofk · 1 shared grant, 2025 · strength 0.85
  10. Kathrin Plath · 1 shared grant, 2025 · strength 0.85
  11. David W. Dawson · 10 shared papers, 2011–2025 · strength 0.59
  12. Aurelia Lugea · 6 shared papers, 2012–2024 · strength 0.58
  13. Xiaoying Sun · 2 shared papers, 2023–2025 · strength 0.45
  14. Richard T. Waldron · 3 shared papers, 2017–2024 · strength 0.43
  15. Howard A. Reber · 11 shared papers, 2011–2016 · strength 0.36
  16. Jonathan C. King · 7 shared papers, 2011–2019 · strength 0.36
  17. Linda Ye · 2 shared papers, 2021–2023 · strength 0.33
  18. Anna S. Gukovskaya · 4 shared papers, 1 shared grant, 2011–2017 · strength 0.29
  19. Roxanne L. Massoumi · 2 shared papers, 2019–2021 · strength 0.29
  20. Mouad Edderkaoui · 5 shared papers, 2012–2019 · strength 0.27
  21. Mu Xu · 3 shared papers, 2016–2018 · strength 0.24
  22. Zobeida Cruz‐Monserrate · 3 shared papers, 2018–2019 · strength 0.22
  23. Murray Korc · 3 shared papers, 2017–2018 · strength 0.21
  24. Dana K. Andersen · 3 shared papers, 2017–2018 · strength 0.21
  25. Sachelly Julián‐Serrano · 1 shared paper, 2022 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.